These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 16379648)

  • 1. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
    McFarlane D; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
    McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
    J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement in histologic assessments of the pituitary pars intermedia in aged horses.
    McFarlane D; Miller LM; Craig LE; Dybdal NO; Habecker PL; Miller MA; Patterson JS; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2055-9. PubMed ID: 16379646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
    Beech J; Boston RC; McFarlane D; Lindborg S
    J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction.
    McFarlane D; Holbrook TC
    J Vet Intern Med; 2008; 22(2):436-42. PubMed ID: 18371032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
    Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
    Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic testing for pituitary pars intermedia dysfunction in horses.
    Dybdal NO; Hargreaves KM; Madigan JE; Gribble DH; Kennedy PC; Stabenfeldt GH
    J Am Vet Med Assoc; 1994 Feb; 204(4):627-32. PubMed ID: 8163420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY; Zylstra R; Haritou SJ
    Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidant enzymes show adaptation to oxidative stress in athletes and increased stress in hemodialysis patients.
    Knap B; Prezelj M; Buturović-Ponikvar J; Ponikvar R; Bren AF
    Ther Apher Dial; 2009 Aug; 13(4):300-5. PubMed ID: 19695063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
    Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
    J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
    Mastro LM; Adams AA; Urschel KL
    Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of proteolytic systems and growth regulators of skeletal muscle in horses with myopathy associated with pituitary pars intermedia dysfunction.
    Aleman M; Nieto JE
    Am J Vet Res; 2010 Jun; 71(6):664-70. PubMed ID: 20513182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    McFarlane D
    Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
    Miller C; Utter ML; Beech J
    Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence for oxidative stress in patients on home parenteral nutrition.
    Schepens MA; Roelofs HM; Peters WH; Wanten GJ
    Clin Nutr; 2006 Dec; 25(6):939-48. PubMed ID: 16777272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.